key: cord-0763864-muhgr8ro
authors: Sadeghizadeh, Atefeh; Pourmoghaddas, Zahra; Zandifar, Alireza; Tara, Seyedeh Zahra; Rahimi, Hamid; Saleh, Rana; Ramezani, Saba; Ghazavi, Mohammadreza; Yaghini, Omid; Hosseini, Neda; Aslani, Nahid; Saadatnia, Mohammad; Vossough, Arastoo
title: Reversible Cerebral Vasoconstriction Syndrome and Multi-System Inflammatory Syndrome in Children with COVID-19
date: 2022-01-05
journal: Pediatr Neurol
DOI: 10.1016/j.pediatrneurol.2021.12.013
sha: 16807427a88a0c4494bcafaefbd3e5c983d853e6
doc_id: 763864
cord_uid: muhgr8ro

BACKGROUND: Multi-system inflammatory syndrome in children (MIS-C) involves multiple organs and shows increased inflammatory markers. Since the onset of the COVID-19 pandemic, several studies have reported the association between severe COVID-19 and MIS-C. Reversible cerebral vasoconstriction syndrome (RCVS) presents with thunderclap headaches and multifocal reversible vasoconstriction on imaging. RCVS is very rare in children. This paper reports two cases of pediatric COVID-19 with severe MIS-C and clinical and imaging features indicative of RCVS. METHODS: Clinical, laboratory and imaging data of the patients were reviewed. The diagnosis of RCVS was confirmed based on clinical symptomatology and brain magnetic resonance imaging findings. RESULTS: Two pediatric patients with clinical findings compatible with severe MIS-C and hemodynamic compromise presented to the hospital. During their hospitalization course, they developed thunderclap headaches and neurological deficits. Both were receiving vasoactive agents, intravenous immune globulin (IVIG), and immunosuppressants. Imaging studies showed marked multifocal cerebral vasoconstriction in both cases and infarcts in one. The course and management of the patients will be presented. After controlling inflammation and elimination of triggers, both patients were ultimately symptom-free upon discharge. Cerebral vasoconstriction had completely resolved on follow-up imaging. CONCLUSIONS: Although a variety of symptoms including headaches may be seen in pediatric COVID-19 patients with MIS-C, RCVS should be considered as a differential diagnosis in cases of thunderclap headache accompanied by neurologic signs in these patients. Imaging findings and follow-up are also key in establishing the diagnosis.

Multisystem inflammatory syndrome in children (MIS-C) can present as an inflammatory response to COVID-19 involving multiple organs such as the heart, gastrointestinal tract, lung, kidneys and nervous system along with increased inflammatory markers [1, 2] . Numerous cases of involvement of the central and peripheral nervous systems have been reported in MIS-C with a variety of clinical presentations including seizures, encephalitis, encephalopathy, stroke, acute disseminated encephalomyelitis, and focal central nervous system involvement [3, 4] . Reversible cerebral vasoconstriction syndrome (RCVS) emerges with severe sudden, recurrent and reversible headaches accompanying multifocal, often bilateral vasoconstriction on imaging with or without focal neurologic signs [5] . This syndrome is quite rare in children, particularly young children, and has only been reported in case reports or very small case series [6] . Recently two adult case reports have been published which reported RCVS in COVID-19 patients [7, 8] .

This paper reports two pediatric COVID-19 patients with severe MIS-C in association with thunderclap headaches and findings of RCVS.

A 10-year-old girl presented with fever, dysentery, and hypovolemia without upper respiratory symptoms and without any known previous medical history. Her blood tests showed cytopenia, high troponin levels, and increased inflammatory markers. She had been in contact with a positive case of COVID-19 one week before admission ( Table 1 ). The patient was diagnosed with severe MIS-C and treated with pulsed methylprednisolone (30 mg/kg, 2 doses) and intravenous immune globulin (IVIG) (2 g/kg), which was continued with 2mg/kg of methylprednisolone. She received epinephrine and milrinone due to hemodynamic instability and left ventricular dysfunction seen on echocardiography.

On the fourth day of hospitalization, she experienced an abrupt severe thunderclap frontal headache, nausea, vomiting, epigastric pain, chest pain and a suspected seizure with upward gaze. She also J o u r n a l P r e -p r o o f complained of diplopia and visual impairment, and ST elevation was observed in her electrocardiogram (ECG). Further tests showed elevated ferritin, troponin, amylase and lipase levels, and ultrasound confirmed pancreatitis. Cardiac CT angiography showed normal coronary arteries. IVIG (2 g/kg) was administered again along with levetiracetam as an anticonvulsant.

She continued to suffer from intermittent abrupt and severe headaches alongside nausea and hypotension. The patient had an episode of seizure with upward gaze and urinary incontinence. The dose of levetiracetam was therefore increased and carbamazepine and gabapentin were added. After four days, brain magnetic resonance imaging (MRI) showed multifocal infarcts ( Figure 1A ). Brain magnetic resonance angiography (MRA) showed widespread multifocal foci of arterial narrowing bilaterally ( Figure   1B ). No subarachnoid hemorrhage was identified. High levels of inflammatory markers such as ferritin were still observed in laboratory investigations. An additional dose of methylprednisolone pulse (20 mg/kg) and a single dose of infliximab (10mg/kg) were administered to control inflammation. The severity and frequency of headaches, symptoms of autonomic dysfunction and involvement of the other organs decreased. Two weeks later, a second dose of infliximab was administered given the insignificant decrease in inflammatory markers, especially ferritin. Inflammatory markers ultimately decreased, lower extremity weakness and cardiac symptoms improved, and headache attacks and autonomic dysfunction were completely alleviated. After 27 days, the patient was discharged in good general condition with fludrocortisone, aspirin and oral prednisolone (2 mg/kg). A two-month follow-up revealed no residual neurologic deficits, and medications were reduced and ultimately discontinued. Follow-up brain MRI and MRA five months later showed residual small foci of chronic infarct and resolution of the areas of vasoconstriction ( Figures 1C and 1D ).

A 6-year-old previously healthy male presented with fever, diarrhea, vomiting, severe abdominal pain, peripheral edema, erythematous lips, and bilateral conjunctivitis. Serological tests were positive for COVID-19 and showed increased inflammatory markers ( Table 1 ). Symptoms of shock which developed J o u r n a l P r e -p r o o f during his hospitalization were treated with fluid therapy, epinephrine and milrinone. Also, the patient received packed cells very early in the first hours of admission because of low hemoglobin.

Echocardiography revealed myocardial dysfunction. The patient was diagnosed with MIS-C and Kawasaki shock syndrome and underwent pulse methylprednisolone therapy (30 mg/kg, 2 doses) and IVIG therapy (2 g/kg) for five days. On the 5 th day of hospitalization, the patient developed an abrupt, severe and thunderclap headache followed by nausea and vomiting. A brain MRI and MRA was performed the following day, showing multifocal bilateral foci of arterial vasoconstriction ( Figure 2A ) but no infarcts.

Vasoactive agents were tapered after improvements in his cardiac function. The patient's headaches resolved around 9-10 th days of hospitalization. On the 11 th day of hospitalization, he developed gross hematuria, proteinuria, dysmorphic red blood cell (60%) and hypertension and was diagnosed with nephritis and therefore underwent a third pulse steroid therapy (30 mg/kg). After 11 days, he was discharged in good general condition, with oral prednisolone (2 mg/kg), aspirin and amlodipine. A one-month clinical followup revealed no neurologic deficits. A six-month follow-up brain MRI and MRA showed complete resolution of vasoconstriction ( Figure 2B ).

We present the first report of two pediatric COVID-19 patients with severe MIS-C who developed severe thunderclap headaches during their treatment course. Brain MRA was consistent with RCVS, and one patient had multifocal infarcts. Follow-up imaging also demonstrated complete resolution of vasoconstriction. Both patients met the criteria of the center for disease control (CDC) definition for MIS-C associated with COVID-19 infection as evidenced by their clinical and laboratory indicators [9] . MIS-C was treated in these patients using IVIG, corticosteroids, and other immunosuppressant agents. Vasoactive agents were administered during their hospitalization due to shock and cardiac dysfunction. Medications were decreased and discontinued after observing improved organ function and inflammatory markers.

Headaches and neurologic signs were not present in the patients at the time of discharge or on follow-up. Complete or marked normalization of arterial changes after 12 weeks, although some patients may not meet all criteria. The pathogenic mechanism is thought to be a transient dysregulation of arterial tone secondary to sympathetic overactivity [5] . Both of our patients fulfill the diagnostic criteria for RCVS. Our patients did not undergo catheter angiography, but that is not a necessary study for the diagnosis of RCVS, and the MRA exams were adequately informative. Recently, a new scoring system named RCVS2 score (range: −2 to 10) has been developed to distinguish RCVS from other intracranial arteriopathies. Although the RCVS2 score has been targeted for young adults, both of our cases had a score higher than five according to this scale which purportedly confirms the diagnosis of RCVS with 94% specificity and 86% sensitivity using the new scoring system [10] . The sudden vasoconstriction may cause daily-to-weekly thunderclap headaches with an approximate duration of 1 minute [11] . Nausea, vomiting and transient hypertension can present during the course of the disease which were observed in all of our patients. Focal neurologic signs are observed in about 43% of cases, including visual impairment, photophobia, blindness, dysarthria and ataxia. Generalized seizures are also reported in 17% of the patients [12, 13] . These focal neurologic signs were observed in our patients and seizure was also noted in one. Ischemic events in RCVS were mostly observed as weakness of the limbs and face typically in the second week [13] , which was seen transiently (less than 24 hours) in one of our cases (case No.1).

Several triggers have been proposed for RCVS such as exercise, swimming, exposure to vasoactive agents and immunosuppressants, transfusion of blood products including IVIG, and various brain diseases [14, 15] . To avoid these triggers, efforts were made to reduce and discontinue the vasoactive agents used to treat hemodynamic instability of the patients immediately after the improvement of their shock and cardiac function. The infusion rate of IVIG was also decreased as well as the intervals between injections since their RCVS symptoms had emerged one to two days after IVIG administration in the course of the disease. 

They speculated that two factors could medicate RCVS in the patient, first, dysfunction of cerebral autoregulation in GBS, and second, IVIG can independently increase serum viscosity, platelet activation, intravascular hypercoagulopathy, and necrotizing microangiopathy which may cause posterior reversible encephalopathy syndrome and stroke [16] . However, in spite of the common use of IVIG and vasoactive substances in pediatrics, RCVS is exceedingly rare in the age group of our patients. Therefore, it is unlikely that IVIG was the cause primary cause of RCVS in our patients. Nevertheless, the question whether COVID-19 and MIS-C could predispose pediatric vasculature to be more susceptible to cerebral vasoconstriction as a result of medication use, remains a possibility. Some research suggests that corticosteroids may worsen the prognosis of RCVS [17] . Nevertheless, corticosteroids were continued due to the underlying disease severity. On the other hand, RCVS is also associated with other inflammatory diseases, including lupus [18] and Takayasu's arteritis [19] . Vascular and endothelial damage caused by immune complexes and autoantibodies in these diseases increases the blood-brain barrier permeability.

These changes have also been suggested as contributing to RCVS [20, 21] . Therefore, managing inflammation with corticosteroids or immunosuppressants may be effective in controlling inflammation, endothelial damage, and possibly subsequent RCVS in MIS-C, although this remains speculative at this time. RCVS is treated based on symptomatic treatment and elimination of triggers [12, 13] , both of which were performed for our patients to the extent possible. Calcium channel blockers have also been suggested [22] . However, it was not feasible to use them in these patients owing to their initial hypotension and cardiac dysfunction.

COVID-19 may induce vasoconstriction [23] and spikes in blood pressure may lead to loss of cerebral autoregulation, which is the proposed mechanism of RCVS. Vasoconstriction is not limited to brain vessels in MIS-C. Gomez et al. showed vasoconstriction plays an important role in causing gastrointestinal complications in pediatric patients with MIS-C associated with COVID-19 [24] . COVID-19 can lead to downregulation of angiotensin-converting enzyme 2, which can cause overactivation of the classic renin-angiotensin axis and lead to vasoconstriction [25] . Only two cases with COVID-19 and RCVS were reported in the literature, albeit in adults [7, 8] . Dakay Vertebral artery dissection was observed on cerebral angiogram. Mild-to-moderate bilateral vasospasm suggestive of RCVS was observed on her imaging seven days later [7] . Mansoor et al. reported a 31-yearold female with RCVS in the setting of mild COVID-19 who was successfully treated with nimodipine and aspirin [8] .

Other arterial abnormalities have been reported in pediatric COVID-19 cases, including focal cerebral arteriopathy (FCA). This entity has been described in two children with COVID-19 and focal neurologic signs in the absence of MIS-C [26, 27] . The first was a 12-year-old male with generalized seizures, right hemiplegia, dysarthria, positive nasopharyngeal swab and cerebrospinal fluid for COVID-19, and FCA of the proximal left middle cerebral artery. The second patient was a 13-year-old female with positive nasopharyngeal polymerase chain reaction (PCR) for COVID-19, persistent headaches, speech impairment and right-sided hemiparesis, without the MIS-C criteria. Imaging revealed an infarct and moderate focal stenosis in the left middle cerebral artery, with wall thickening and contrast enhancement on vascular wall imaging, confirming the inflammatory type of FCA [27] . Given the clinical signs and characteristic imaging findings in these two cases, our patients do not fit the diagnosis of FCA. Thunderclap headache was the main initial neurologic symptom in our patients. Multifocal and bilateral vasoconstriction was observed on imaging and was shown to be transient and reversible on follow-up, as required for the confirmation of RCVS. On the other hand, FCA is associated with focal neurologic signs, altered levels of consciousness, and sometimes seizures rather than with severe and abrupt headaches. The pattern of vascular involvement did not match the pattern seen in FCA [28, 29] . Similarly, the clinical presentation of severe thunderclap headaches in RCVS, which may recur daily, is not typical for primary CNS vasculitis.

Numerous neurological manifestations have been reported in patients with MIS-C. Headaches [30] and restlessness [31] with incidences of 26% and 57%, respectively, have been reported as the most prevalent symptoms. A study on 186 patients with MIS-C reported neurologic signs, including encephalitis, seizures and altered levels of consciousness in 11% of the cases [32] . Moreover, encephalopathy, headache, J o u r n a l P r e -p r o o f

Hyperinflammatory shock in children during COVID-19 pandemic

CDC COVID-19 Response Team. Coronavirus Disease 2019 in Children -United States

Neurological manifestations of pediatric multi-system inflammatory syndrome potentially associated with COVID-19

Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children

Narrative review: reversible cerebral vasoconstriction syndromes

Reversible cerebral vasoconstriction syndrome in pediatrics: A case series and review

Reversible cerebral vasoconstriction syndrome and dissection in the setting of COVID-19 infection

Associated Reversible Cerebral Vasoconstriction Syndrome Successfully Treated with Nimodipine and Aspirin

Information for Healthcare Providers about Multisystem Inflammatory Syndrome in Children (MIS-C) | CDC n

RCVS2 score and diagnostic approach for reversible cerebral vasoconstriction syndrome

Reversible cerebral vasoconstriction syndrome: an underrecognized clinical emergency

Reversible cerebral vasoconstriction syndromes: analysis of 139 cases

Systematic review of reversible cerebral vasoconstriction syndrome

Reversible cerebral vasoconstriction syndrome: current and future perspectives

Reversible cerebral vasoconstriction syndrome

Reversible Cerebral Vasoconstriction Syndrome following Guillain-Barré Syndrome: A Rare Complication

Glucocorticoid-associated worsening in reversible cerebral vasoconstriction syndrome

Reversible cerebral vasoconstriction syndrome in paediatric patients with systemic lupus erythematosus: implications for management

Reversible cerebral vasoconstriction syndrome in a patient with Takayasu's arteritis

Blood-brain barrier breakdown in reversible cerebral vasoconstriction syndrome: Implications for pathophysiology and diagnosis

Blood-Brain Barrier Permeability in Patients With Reversible Cerebral Vasoconstriction Syndrome Assessed With Dynamic Contrast-Enhanced MRI

The clinical and radiological spectrum of reversible cerebral vasoconstriction syndrome. A prospective series of 67 patients

COVID-19 and intracerebral haemorrhage: causative or coincidental?

Abdominal manifestation of multisystemic inflammatory syndrome in children

Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights

Focal Cerebral Arteriopathy in a Pediatric Patient with COVID-19

Vessel Wall Enhancement and Focal Cerebral Arteriopathy in a Pediatric Patient with Acute Infarct and COVID-19 Infection

Reversible cerebral vasoconstriction syndrome or primary angiitis of the central nervous system?

Vessel wall MRI to differentiate between reversible cerebral vasoconstriction syndrome and central nervous system vasculitis: preliminary results

Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2

Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study

Multisystem inflammatory syndrome in U.S. children and adolescents

Lesions in the splenium of the corpus callosum on MRI in children: A review